The conditions favouring effective specific cytotoxic T lymphocyte (CTL) priming have been exploited to set up a simple and reproducible method to Induce a primary CTL response In vitro. We report that cultured monocytes, as well as activated T cells, pulsed with exogenous HLA-A2 binding immunogenic peptides, can induce primary peptlde-specific CTL responses In vitro in a T h -lndependent manner. Primary viral peptide-induced CTL were HLA-A2 restricted, and recognized both peptlde-pulsed target cells and targets infected with recomblnant vaccinia virus expressing viral endogenous antigens. In addition, both cultured monocytes and activated T cells primed peptide-speciflc CD8 + T cells depleted from the CD45RO+ memory cell fraction. The efficiency of CTL priming by monocytes was dependent upon the strong up-regulation of class I, adhesion and co-stimulatory molecules occurring spontaneously upon In vitro culture. The Inability of unseparated peripheral blood mononuclear cells to mount a peptlde-speclflc CTL response could be reverted by direct co-stimulation of responding CD8 + T cells by soluble B7.1 or a stimulatory anti-CD28 antibody, that allowed a specific response to take place. Although co-stimulation via the B7-CD28 interaction appeared sufficient to trigger CTL responses, it was not essential for CTL priming, since neither anti-B7.1 mAb nor soluble CTLA-4 Inhibited Induction of primary CTL response. This new method for Induction of specific CD8
Introduction
Recent advances in understanding the interaction between naturally processed peptides and MHC molecules allow the identification of the likely immunogenic peptides in a protein sequence on the basis of the presence of specific anchors (1) . Peptides binding to MHC class I molecules, which are in general 9-10 residues long, usually contain within their sequence two anchor residues interacting with corresponding binding pockets in the MHC molecule (2) (3) (4) . The binding can be measured in vitro by demonstrating the capacity of the synthetic peptide to assist the folding of a particular class I molecule (1, (5) (6) (7) . Definition of specific MHC motifs allows us to predict those peptides derived from viral or tumor antigens, potentially immunogenic for CTL.
Synthetic peptides have been used not only to identify the epitopes of a protein recognized by specific cytotoxic T lymphocytes (CTL), but also as vaccines to induce protective CTL in mouse (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Moreover, peptides conjugated to either a helper epitope or lipid have been used to induce protective CTL responses (21, 22) . Alternatively, with regard to adoptive immunotherapy, i.e. in cancer patients or in severe immuno-compromised HIV carriers, one of the two following approaches may be considered: either the in vivo transfer of in wrro-primed, well characterized peptide-specific CTL, or peptide vaccination using well characterized peptides, that could be delivered on professional APC.
However, it would be desirable to set up a simple and reproducible method to induce primary antigen-specific CTL response in vitro. Indeed, such an approach may be essential to identify not only immunogenic peptides, but also the most appropriate professional APC capable of triggering CTL precursors. The prerequisite for such APC is to present a high density of peptide-MHC molecule complexes (signal 1) and to simultaneously deliver the co-stimulatory signals (signal 2) required for T cell activation, which has been defined as B7.1 or B7.2 interacting with CD28/CTLA-4 on T cells (23) (24) (25) (26) .
The strategies to induce primary CTL responses in vitro and the conditions that determine effective CTL priming as well as unfavourable conditions are reported herein.
Methods

Identification of HLA-A2.1 binding peptides
Peptides of HIVgp120 and hepatitis B envelope antigen (HBenvAg; subtype ADW2) carrying HLA-A2.1 motif (1) were synthesized by the solid-phase method on an automated multiple peptide synthesizer (AMS 422; Abimed, Langenfeld, Germany) using Fmoc chemistry. The purity of peptides was determined by reverse-phase HPLC. Peptides were diluted to a concentration of 2 mg/ml and stored at -20°C. The peptides were screened for their ability to stabilize HLA-A2.1 molecules on the surface of transporter defective mutant T2 cells (27, 28) . T2 cells were cultured in RPMI 1640 (HyClone, Logan, UT) supplemented with 10% FCS (HyClone), 2 mM Lglutamine, 1% sodium pyruvate, 100 U/ml penicillin, 100 jig/ ml streptomycin and 2 jig/ml fungizone (Flow, Irvine, UK) (complete medium). T2 cells were washed twice and resuspended in either serum-free medium in the presence of 10 \iglm\ human f^microglobulin (fern) (Sigma, St Louis, MO) or complete medium and incubated in 96-well flat-bottom plates in the presence or absence of different concentrations of peptide overnight at 37°C, 5% CO 2 . Cells were washed and stained with an anti-HLA-A2.1 mAb (lgG2a, BB7.2; ATCC, Rockville, MD) for 30 min at 4°C followed by FITC-F(ab)' 2 goat anti-mouse Ig (GAM). Cells were washed twice and analysed using a FACScan (Becton Dickinson, Mountain View, CA).
Peptides showing high levels of stabilization of class I on T2 cells were studied for their ability to bind HLA-A2.1 by a direct binding assay, that is based on serologic detection of the conformational change of HLA class I a-chains induced by binding to specific peptides in the presence of fem, as described (29) . Briefly, Epstein-Barr virus transformed-B (EBV-B) cells were lysed in Tris-HCI, pH 7.5, containing 0.5% NP-40 and protease inhibitors, and the lysates were denaturated by alkaline dissociation. The unfolded a-chain was separated from fern and peptides by gel filtration. The fractions containing the first major protein peak were pooled and incubated with test peptides and excess p 2 m for 16 h at 25 C C. The increase in folded a-chain activity induced by peptide binding was quantitated by a specific radioimmunoassay involving a rabbit anti-HLA class I serum and 125 l-labelled purified HLA-A2.1 molecules.
Purification of CD8* T cells
Human peripheral blood mononuclear cells (PBMC) were isolated from HLA-A2 + healthy donors on Lymphoprep cushions (LSM; Organon Teknika, Durham, NC). Donors were negative for HBV and HIV serological markers. PBMC were then washed in serum-free medium and allowed to adhere to 24-well plates (Falcon) in RPMI-1% human AB serum. After 90 min at 37°C the non-adherent cells were removed and used for cell purification as described (30) . Briefly, CD8 + T cells were isolated by immunomagnetic separation with anti-CD8 mAb attached to Dynabeads (Dynal, Oslo, Norway). Positively selected cells were detached from magnetic beads by incubation with Detachabead (Dynal) according to the manufacturer's instructions. After the treatment, purified CD8 + and CD8"T cells were >98% CD8 + and <1% CD8~ respectively. In some experiments, a CD45RA + CD45RO~ population was isolated from purified CD8 + T cells by depletion of CD45R0"
" cells with anti-CD45RO
+ mAb attached to magnetic beads.
In vitro priming with peptide
PBMC (4-5X10 6 ) were incubated in RPMI-1% human AB serum in culture 24-well culture plates (Falcon) for 90 min at 37°C, 5% CO 2 ; the non-adherent cells were removed, and the adherent fraction was pulsed with different concentrations of peptide in serum-free medium for 4 h and used as APC. Adherent cells were then incubated with 1.5X10 6 responding purified CD8 + T cells in the presence or absence of different concentrations of an anti-B7.1 mAb (31) or a fusion protein between human CTLA-4 and human lgG1 (huCTLA-4-hulgGI) (32) . In some experiments we used as APC either an irradiated (3000 rad) autologous T cell clone, or irradiated (3000 rad) autologous PBMC or irradiated (13,000 rad) autologous EBV-B cells. In some experiments, either a fusion protein between human B7.1 and IgM (huB7.1-lgM) or an anti-CD28 mAb were added to cultures in which irradiated PBMC were used as APC.
In all cases after 2 days of culture, 50 U/ml rlL-2 (Proleukin; Eurocetus, Emeryville, CA) was added and after a further 5 days, CD8 + T cells were re-stimulated with irradiated autologous phytohaemagluttinin (PHA)-T cell blasts pulsed with 10 ng/ml peptide. After a second administration of IL-2, viable CD8 + T cells from each culture were tested for specific cytotoxicity on day 7 from the secondary stimulation.
Generation of CTL clones
T cell clones were isolated and maintained as previously described (33) . Briefly, primary peptide-specific CTL were cloned by limiting dilution at 0.3 cells/well onto 96-well Ubottom plates in the presence of 0.5 ng/ml PHA-P (Wellcome Beckenham, UK), 50 U/ml rlL-2 and irradiated allogeneic feeder cells. After 2-3 weeks, cell growth was detected using an inverted microscope and growing cultures were tested for their capacity to mount a specific cytotoxic response to peptide-pulsed 51 Cr-labelled target cells. Peptide-specific CTL clones were then expanded in rll-2-containing medium and maintained in culture with 2 week cycles of re-stimulation with PHA plus allogeneic APC.
CTL assay
Cytotoxicity of CD8
+ T cells, primed with peptide-pulsed APC, was tested in a 6 h 51 Cr-release assay. T cells were used as effector cells at an E:T ratio ranging from 50:1 to 20:1. Effector cells were incubated in triplicate in U-bottom microtitre wells (Falcon), containing 5X10 3 51 Cr-labelled homozygous HLA-A2.1+ EBV-B cells. Target cells were labelled with 100 nCi of Na 51 Cr (Amersham, Buckinghamshire, UK) for 2 h and then pulsed with 10 ng/ml peptide for 1 h at 4°C or left unpulsed. In some experiments anti-HLA-A2 mAb or an anti-HLA-B27 mAb were added at the initiation of the assay.
In some experiments, EBV-B cells infected with recombinant vaccinia virus (rW) expressing gp160 (VPE16) or with VSC8 as control were used as target cells. The rW were kindly donated by Andrea De Maria (University of Genova, Italy). EBV-B cells (1.5X10 6 ) were incubated with 1 p.f.u./ixiO 6 cells of the different preparations of rW at 4°C for 10 min, washed and resuspended in 5 ml complete medium and incubated at 37°C, 5% CO 2 , for 12 h before being used as target cells.
F7\CS analysis
The following purified specific mAb were used: anti-CD3 (lgG1, TR66), anti-CD4 (IgGI, 6D10), anti-HLA-A2. Cells were labelled with mAb on ice for 30 min, washed four times, incubated for 30 min on ice with FITC-F(ab)' 2 GAM Ig, washed again and immediately analysed on FACScan flow cytometer (Becton Dickinson) equipped with a 15 mW aircooled 488 nm argon-ion laser. The cytometer was calibrated using three different types of CaliBRITE (Becton Dickinson) beads of -6.6 |im in diameter. Gating was performed using a combination of forward and orthogonal light scatter (linear amplification). Propidium iodide was used to exclude dead cells. Data of 10,000 events was acquired and stored in list mode using the FACScan research software. The Lysys 111.1 program was used for analysis of data.
Soluble human B7.1-lgM molecule
The generation and characterization of the soluble huB7.1-IgM will be described in detail elsewhere (P. Dellabona and G. Casorati, manuscript in preparation). Briefly, total Antigen-specific CTL priming 1743 cytoplasmic RNA extracted from an EBV-transformed cell line was reverse transcribed into cDNA, and the sequence encoding for the extracellular domains of the human B7.1 molecule was amplified by PCR using the following oligonucleotide: 5'-CCTGAGCTCCTGAAGCCATGGGCCACACACGG-3' and 5'-TCTGACTTACCATCAGGAAAATGCTCTTGCTT-3' (underlined is a consensus splicing donor site). The PCR was run with the following conditions: 20 s at 94°C, 30 s at 60°C and 30 s at 72°C for 20 cycles. The amplified product was cloned blunt ended into the pBluescript vector, sequenced to rule out PCR errors and subcloned into the Ssfl-SaA digested pCD4-hCu expression vector. The huB7.1-lgM was transfected by protoplast fusion into the mouse plasmocytoma cell line J558L as described (35) and the clones secreting the highest amount of proteins (3-5 |ig/ml) were selected for expansion.
The approximate size of the B7.1-lgM was determined on an SDS-PAGE gel. Briefly, the B7.1-lgM protein was precipitated from culture supernatant using the anti-B7.1 mAb B7.24 (31) and Protein G (Pharmacia, Uppsala, Sweden), run on an SDS-PAGE both in reducing and non-reducing conditions, and blotted on a nitrocellulose filter. The filter was decorated with alkaline phosphatase-labelled GAM Ig (Southern Biotechnology, Birmingham, AL) followed by ECL (Amersham). Under reducing conditions, the B7.1-lgM migrated as a single molecular species of -130 kDa, while under non-reducing condition it migrated with an apparent M r of 700, consistent with the pentameric structure determined by the IgM Fc portion. To prepare the B7.1-lgM containing supernatant, the J558L clone secreting it was grown in standard RPMI medium (Hyclone) containing 7% FCS in a Miniperm fermenter (Haereus, Germany). We determined as 1:10 the optimal dilution of B7.1-lgM containing supernatant giving the highest proliferative response on purified human CD4 + CD45RO T cells, stimulated with a suboptimal dose of anti-CD3 mAb. The proliferative response was measured by 
Results
Identification of HLA-A2 binding peptides
T cell determinants to be used for the induction of CTL responses in vitro were identified using the known HLA-A2 binding motif (5, 6) . Forty-eight nonamers carrying the A2 motif were screened for their capacity to stabilize HLA-A2 molecules on the surface of the transporter defective mutant T2 cells essentially as described (36) . A peptide of HIVgp120 (121-129; KLTPLCVSL) and a peptide of HBenvAg (335-343; WLSLLVPFV), that showed high levels of binding, were selected for functional experiments, according to our preliminary experiments demonstrating that CTL specific for those peptides efficiently cross-reacted on endogenous antigen presenting target cells. As shown in Rg. 1, these peptides can stabilize cell surface A2 molecules on T2 cells and can assist the refolding of isolated A2 a chains in the presence of fern.
Characterization of APC for in vitro priming
Initial attempts to induce primary CTL responses by directly adding the HLA-A2 binding peptides to PBMC of HLA A2 + donors were unsuccessful (data not shown). We reasoned that the failure to induce a specific response might be due either to insufficient number of sites available on APC or to inappropriate presentation, i.e. presentation on non-professional APC (26) or on the responding T cells themselves (37) . We therefore asked whether selective display of the peptide on professional APC may favour stimulatory interactions and lead to CTL priming. We tested different sources of APC: PBMC, EBV-B cells, the transporter mutant T2 that can be efficiently loaded with peptide, autologous T cell clones and adherent cells. Consistent stimulation of a peptide-specific response was obtained only when either adherent cells or T cell clones were used as APC. EBV-transformed autologous B cells and to a higher extent, T2 cells induced a very strong non-peptidespecific response that obscured a specific response. presentation of peptide and T cell priming. As previously reported, human activated T cell clones express high levels of the same molecules and display 'professional' antigen presenting capacity (38, 39) .
Conditions for the generation of primary CTL responses using peptide-pulsed APC
A general protocol for the generation of specific CTL responses in vitro was developed. PBMC (4-5X10 6 ) were incubated in 24-well culture plates for 90 min; the nonadherent cells were removed and the adherent fraction was extensively washed to deplete contaminating T and B cells and pulsed with different concentrations of peptide. Due to the low frequency of peptide-specific T cells in an unprimed donor, we set up several replicate 2 ml cultures containing adherent cells and 1.5X10 6 responding purified (>98%) CD8 + T cells. Alternatively, responding CD8 + T cells were cultured with the aforementioned APC (1 x10 6 ), that had been previously pulsed with different concentrations of peptide. Anyway, after 2 days, IL-2 (50 U/ml) was added and the cultures were incubated for an additional 5 days before secondary stimulation with 10 6 irradiated autologous T cell blasts that had been pulsed with 10 u,g/ml peptide. After a further 7 days, the cultures were individually tested for specific cytotoxicity against homozygous HLA-A2 + EBV-B cells pulsed or not with peptide.
As evident from a typical experiment reported in Fig. 2 , monocytes pulsed with 100 ng/ml peptide induce a peptidespecific cytotoxic response detectable in 12 out of 20 replicate cultures. When autologous activated T cell clones were used as a source of peptide-pulsed APC a similar cytotoxic response was obtained (Fig. 2) . In contrast, no specific response was obtained when either peptide-pulsed PBMC (Fig. 2) , T2 cells or EBV-B cells (not shown) were used as APC. In all cases the responding T cells were peptide specific and HLA-A2 restricted, as shown by the inhibition of killing by an anti-HLA-A2 antibody. Similar results were obtained in 10 out of 14 healthy donors tested. Figure 3 clearly shows that CTL activity was specific for the peptide used in the priming, since target cells incubated with an HLA-A2.1 binding control peptide were not lysed.
Further evidence for selective priming of CTL by activated monocytes was obtained from cytofluorimetric analysis. When unfractionated HLA-A2+ PBMC were cultured with peptidepulsed monocytes a selective expansion of CD8 + T cells was detected on day 7 (not shown).
Interestingly, we noticed that the optimal timing for peptide loading on monocytes coincides with the first 4 h of in vitro culture when there is a maximum increase of surface class I molecules (Fig. 4 and Table 1 ).
We conclude that (i) when the only interactions allowed are those between specific CTL precursor and monocytes or T cell clones, a CTL response can be readily induced; (ii) in this case, induction of a primary CTL response triggered by professional APC does not require CD4 + T cells; and (iii) failure of total PBMC to mount a CTL response to soluble peptide cannot be explained by insufficient peptide loading, but rather by the presence of inappropriate interactions. 
Co-stimulatory requirements for the induction of a primary CTL response
The fact that peptide presentation by monocytes or T cell clones is effective, while presentation by total PBMC (which include monocytes as well) is not, suggests that total PBMC contain cells capable of presenting the peptide in a 'suppressing' fashion. To test whether the inability of PBMC to mount a peptide-specific CTL response was determined by presentation of peptide on cells that lack co-stimulatory signals, we asked whether soluble molecules that directly Highly purified CD8 + T cells were primed with monocytes that were pulsed with gp 120(121-129) peptide for 4 h either immediately after 90 min adherence or after 24 h in vitro culture. Thereafter, they were re-stimulated and assayed for cytotoxicity against peptide-pulsed (hatched bars) or unpulsed (solid bars) target cells, as described, at an E:T ratio 25:1. The percentage of the specific CTL lines generated with the two conditions was reported. A CTL line was defined specific when it expressed a specific lysisof >15%. Peptide-pulsed unseparated PBMC, used as a source of APC, were cultured with purified CD8 + T cells in the absence or presence of either chimeric huB7.1-lgM molecules Of mouse anti-CD28 IgM antibodies. After 7 days, the cells were re-stimulated, as previously described, and after a further 7 days, were tested in a cytotoxicity assay against peptide-pulsed (hatched bars) or unpulsed (solid bars) target cells, as described, at an E:T ratio 25:1. Results represent the percentage mean of specific lysis expressed by all the specific CTL lines.
deliver the co-stimulatory signal to T cells might reverse this effect. When a huB7.1-lgM chimeric protein or an IgM anti-CD28 mAb was added to unseparated PBMC and peptide, a clear CTL response was detected (Fig. 5 ). These results demonstrate that co-stimulation via CD28 is sufficient for the induction of the CTL response and suggest that peptide presentation on frequent non-professional APC present among PBMC (resting T and B cells expressing class I but not co-stimulatory molecules) may induce peptide-specific anergy in CTL precursors.
To further study the co-stimulatory requirements for the induction of a primary anti-peptide response, we tested the blocking effect of anti-B7.1 mAb or soluble CTLA-4, that can bind with high affinity to both B7.1 and B7.2. Interestingly, neither anti-B7.1 nor soluble CTLA-4 was able to significantly inhibit the induction of a primary peptide-specific CTL response by activated monocytes (Fig. 6) . Similar results were obtained using autologous activated T cells as APC (not shown). Control experiments showed that both anti-B7.1 mAb and soluble CTLA-4, both added at 5 u.g/ml at the initiation of culture, significantly blocked the proliferative response by resting T cells in a primary mixed lymphocyte reaction stimulated by either T cell clones or monocytes or dendritic cells (not shown). These results suggest that, in addition to B7.1/B7.2 molecules, professional APC may possess additional co-stimulatory ligands that are sufficient for the induction of a CTL response. Thus, it appears that each of the two pathways is in itself sufficient, although not strictly necessary for CTL activation.
Characterization of the responding T cells
To investigate whether the CTL response was due to in vitro priming of virgin CTL precursors or to the reactivation of memory cells that had been primed in vivo by the same or cross-reacting peptides, we compared the response of total
CD8
+ T cells with that of CD8 + T cells depleted of CD45RO + putative memory T cells. As shown in Table 2 , the CTL response was comparable in both populations, indicating that the contribution to the response of CD45RO + cells (usually only 10-20% of total CD8 + ) is indeed negligible. We cannot exclude, however, that the responding cells may belong to a population of resting CD45RA" 1 " cells that had reverted from CD45RO+ cells.
CTL obtained by in vitro priming with synthetic peptides recognize naturally processed peptides on infected cells
We tested whether the primary peptide-specific CD8 + T cells were able to recognize naturally processed peptides derived "Unseparated CD8+ T cells or CD45RO depleted-CD8 + T cells (CD8 + CD45RO" T cells), sorted from peripheral blood as described in Methods, were cultured with peptide-pulsed adherent monocytes for 7 days followed by re-stimulation with peptide-pulsed autologous T cell blasts. Afterwards they were tested for their capacity to kill 51 Cr-labelled EBV-B cells, pulsed or not with peptide. Percentage of specific lysis is expressed as mean of triplicate determinations.
from endogenously synthesized proteins. Out of eight HIVgp120(121-129) peptide-specific CTL lines tested, five efficiently cross-reacted on HLA-A2 + EBV-B cells infected with rW expressing HIVgp160 (Fig. 7 ). Figure 7 also shows that two representative CD8 + T cell clones, generated from HIVgp120(121-129) peptide-primed T cells, killed both the peptide-sensitized A2 + EBV-B cells and the same targets endogenously expressing HIVgp160. Similarly, CD8 + T cell clones specific for HBenvAg(335-343) peptide recognized EBV-B cells infected with rW expressing HBenvAg (not shown).
Discussion
In the perspective of an adoptive immunotherapy, it is important to generate in vitro primary CTL responses, i.e. responses to antigens to which the individual has not been primed in vivo. We used two nonamer HLA-A2 binding peptides from HIVgp120 and HBenvAg to define the conditions for the generation of such CTL responses by CD8 + cells from seronegative donors. A critical factor appeared to be the mode of antigen presentation. While peptide pulsing of unseparated PBMC was invariably ineffective, pulsing of adherent monocytes or activated T cells with peptide induced a peptidespecific, HLA-A2-restricted CTL response. The responding CD8 + T cells recognize naturally processed peptides on target cells infected with rW expressing HIVgp160. This last is a fundamental requirement in the perspective of adoptive immunotherapy, in which specific CTL have to recognize peptides expressed in association with class I molecules on the surface of host tumor or infected cells, as a product of endogenous processing. Indeed, the majority of our peptidespecific CTL lines tested, as well as the CTL clones derived from them, efficiently killed infected target cells, confirming previous reports indicating that the immunodominant peptides always belong to the highest HLA-binding peptides (10, 14, 17) .
Previous attempts to generate primary in vitro CTL responses in the mouse system involved the use of either dendritic cells, which possess high stimulatory capacity (40) , or of the transporter defective mutant RMA-S, which expresses high levels of empty MHC molecules (12) . Recently, human dendritic cells have been demonstrated to be very efficient APC in priming both naive CD4 + and CD8 + T cells (41, 42) . Moreover, the report by Houbiers et al. describes the generation of primary peptide-specific CTL responses in humans after in vitro stimulation with mutant T2 cells (43) . This protocol was not successful in our hands. Indeed, in preliminary experiments we found that the human transporter defective mutant T2 cells, although able to bind high peptide levels ( Fig. 1) , was not suitable for in vitro priming, because of the very high level of background activation.
Out of all APC tested, only monocytes and T cell clones gave reproducible results. The fact that cultured monocytes are efficient for CTL priming implies that they can bind sufficient amounts of peptide and present it in the appropriate co-stimulatory context. This efficient presentation may be dependent upon the strong up-regulation of MHC class I, as well as adhesion and co-stimulatory molecules that appear spontaneously upon in vitro culture within the first 2-6 hours (Table 1 ) (44), as shown by the fact that adherent monocytes are much more effective if pulsed in the first few hours of culture. The peptide pulsing, done during the up-regulation of class I molecules by APC, may favour a more efficient peptide binding to that small percentage of newly synthesized empty class I molecules, available to bind exogenous peptides.
We also found that autologous activated T cell clones can function as APC for CTL priming with antigenic peptides. An advantage in the use of activated T cells is the lack of a very low non-specific background of stimulation in the absence of peptide. We and others have previously demonstrated that activated T cell clones are indeed professional APC and very effective in priming other T cells (38, 39) .
Recently, an alternative approach for inducing primary antitumor CTL in humans was successfully carried out using as APC non-transformed B cell blasts (45) . This together with the finding that EBV-transformed B cells used as APC were not able, in our system, to prime antigen-specific CTL responses, suggests that the two B cell preparations have different APC capabilities.
It has been previously reported that the density of T cell epitopes required for the induction of primary CTL response is much higher than the concentration required for secondary responses (12) . This difference is evident also in the induction of human CTL, since a 10-fold lower peptide concentration is required to sensitize target cells for killing.
There are three points that need further discussion. First, as reported in several experimental systems (12, 32, (46) (47) (48) (49) , our data demonstrate that, when antigen is presented by professional APC, the requirement for antigen-specific T h cells in the induction of CTL may not be evident. This result gives rise to speculation that CTL precursors primed by professional APC do not require T h cooperation, that is instead essential when antigen is presented by non-professional APC; in this last instance, activated T cells themselves, working as professional APC (39) , could simultaneously present peptide and provide co-stimulation for an appropriate CTL priming.
The second point concerns the pathway of co-stimulation. Our results demonstrate that direct co-stimulation of responding CD8 + T cells by soluble ligands via CD28 can revert the inability of peptide presentation by non-professional APC. In apparent contrast, however, we found that anti-B7.1 antibody as well as soluble CTLA-4 that blocks both B7.1 and B7.2 (24, 25) fail to inhibit induction of a specific CTL response by activated monocytes. These results suggest that the B7^CD28 interaction, although by itself sufficient for priming, is not strictly necessary and that alternative costimulatory pathways may exist. Similar conclusions have been recently reached by Johnson and Jenkins in an anti-CD3-dependent T cell activation system (50) .
Finally, our data favour the idea that a real CTL priming is carried out by virgin T cells in our system for two reasons: (i) the donors were healthy and seronegative and (ii) the depletion of CD45RO + cells did not affect the CTL response, indicating that most of the responding cells belong to the RA + ROc ompartment, even though we cannot exclude that this last population may contain some CD45RA + resting T cells that have reverted from memory CD45RO + phenotype (51, 52 ).
In conclusion, exploiting the strategies affected by the immune system for inducing a primary T cell response, we define a protocol of CTL priming, by using activated monocytes or T cell clones as professional APC, well defined HLAbinding peptides as immunogenic antigen, and the conditions favouring productive interactions between specific CTL precursors and professional APC.
